The 2022 STEP Trial revealed that one year after discontinuing once-weekly semaglutide, participants regained two-thirds of their previous weight loss, with similar reversals in cardiometabolic improvements
This analysis included semaglutide, further supporting the idea that it is unlikely to cause blood clots
Additionally, Semaglutide is safe for long-term use, a major advantage over other weight loss medication alternatives
Despite their potential to potentiate SDF-1 and thereby exacerbate the vascular complications of type 2 diabetes, DPP-4 inhibitors have emerged as a popular choice for the treatment of the disease because of their ease of use, tolerability and ability to produce predictable and sustained lowering of blood glucose
This is because orforglipron is a small molecule absorbed through passive diffusion in the small intestine, rather than a peptide requiring the SNAC absorption enhancer and stomach-specific absorption conditions needed by Rybelsus